Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT02207231




Registration number
NCT02207231
Ethics application status
Date submitted
31/07/2014
Date registered
4/08/2014
Date last updated
23/07/2021

Titles & IDs
Public title
A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis
Scientific title
Phase 3, Multicenter, Randomized, Double-blind, Placebo and Active Comparator-controlled Study Evaluating the Efficacy and Safety of Guselkumab in the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis
Secondary ID [1] 0 0
CNTO1959PSO3001
Secondary ID [2] 0 0
CR105047
Universal Trial Number (UTN)
Trial acronym
VOYAGE 1
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Psoriasis 0 0
Condition category
Condition code
Skin 0 0 0 0
Dermatological conditions
Skin 0 0 0 0
Other skin conditions

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Guselkumab 100 mg
Treatment: Drugs - Placebo for guselkumab
Treatment: Drugs - Adalimumab
Treatment: Drugs - Placebo for adalimumab

Experimental: Group I - Participants received Guselkumab 100 milligram (mg) at Weeks 0, 4, and 12 and every 8 weeks (q8w) thereafter through Week 252, placebo for guselkumab at Week 16, and placebo for adalimumab (two 0.8 milliliter [mL] injections) at Week 0 followed by one 0.8 mL injection at Weeks 1, 3, and 5, and every 2 weeks (q2w) thereafter through Week 47.

Placebo Comparator: Group II - Participants received Placebo for guselkumab at Weeks 0, 4, and 12, and placebo for adalimumab (two 0.8 mL injections) at Week 0, followed by one 0.8 mL injection at Weeks 1, 3, and 5, and q2w through Week 15. At Week 16, placebo participants will cross over to receive guselkumab 100 mg at Weeks 16 and 20 and q8w thereafter through Week 252, as well as placebo for adalimumab at Weeks 17, 19, 21, and 23, and q2w thereafter through Week 47.

Active Comparator: Group III - Participants received Adalimumab 80 mg at Week 0 (two 40 mg [0.8 mL] injections) and 40 mg at Weeks 1, 3, 5, and q2w thereafter through Week 47, placebo for guselkumab at Weeks 0, 4, 12, 16, and 20, and q8w thereafter through Week 44 and guselkumab 100 mg at Weeks 52, 60, and q8w thereafter through Week 252.


Treatment: Drugs: Guselkumab 100 mg
100 mg by subcutaneous injection at Weeks 0, 4 and q8w thereafter through Week 252 (Group 1). 100 mg by subcutaneous injection at Weeks 16, 20 and q8w thereafter through Week 252 (Group II). 100 mg by subcutaneous injection at Week 52 and q8w thereafter through Week 252 (Group III).

Treatment: Drugs: Placebo for guselkumab
Subcutaneous injections to maintain the blind.

Treatment: Drugs: Adalimumab
80 mg by subcutaneous injection at Week 0, then 40 mg at Week 1 and every 2 weeks (q2w) thereafter through Week 47.

Treatment: Drugs: Placebo for adalimumab
Subcutaneous injections to maintain the blind.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Percentage of Participants Who Achieved an Investigator's Global Assessment (IGA) Score of Cleared (0) or Minimal (1) in the Guselkumab Group Compared to the Placebo Group at Week 16
Timepoint [1] 0 0
Week 16
Primary outcome [2] 0 0
Percentage of Participants Who Achieved Psoriasis Area and Severity Index (PASI) 90 Response in the Guselkumab Group Compared to the Placebo Group at Week 16
Timepoint [2] 0 0
Week 16
Secondary outcome [1] 0 0
Percentage of Participants Who Achieved an Investigator's Global Assessment (IGA) Score of Cleared (0) in the Guselkumab Group Compared to the Adalimumab Group at Week 24 and 48
Timepoint [1] 0 0
Week 24 and 48
Secondary outcome [2] 0 0
Percentage of Participants Who Achieved an Investigator's Global Assessment (IGA) Score of Cleared (0) or Minimal (1) in the Guselkumab Group Compared to the Adalimumab Group at Week 24 and 48
Timepoint [2] 0 0
Week 24 and 48
Secondary outcome [3] 0 0
Percentage of Participants Who Achieved Psoriasis Area and Severity Index (PASI) 90 Response in the Guselkumab Group Compared to the Adalimumab Group at Week 24 and 48
Timepoint [3] 0 0
Week 24 and 48
Secondary outcome [4] 0 0
Change From Baseline in Dermatology Life Quality Index (DLQI) Score at Week 16 in the Guselkumab Group Compared to the Placebo Group
Timepoint [4] 0 0
Baseline, Week 16
Secondary outcome [5] 0 0
Percentage of Participants Who Achieved an Investigator's Global Assessment (IGA) Score of Cleared (0) or Minimal (1) in the Guselkumab Group Compared to the Adalimumab Group at Week 16
Timepoint [5] 0 0
Week 16
Secondary outcome [6] 0 0
Percentage of Participants Who Achieved Psoriasis Area and Severity Index (PASI) 90 Response in the Guselkumab Group Compared to the Adalimumab Group at Week 16
Timepoint [6] 0 0
Week 16
Secondary outcome [7] 0 0
Percentage of Participants Who Achieved Psoriasis Area and Severity Index (PASI) 75 Response in the Guselkumab Group Compared to the Adalimumab Group at Week 16
Timepoint [7] 0 0
Week 16
Secondary outcome [8] 0 0
Percentage of Participants Who Achieved a Scalp-specific Investigator's Global Assessment (Ss-IGA) Score of 0 or 1 and at Least a 2-Grade Improvement From Baseline at Week 16 in the Guselkumab Group Compared to the Placebo Group
Timepoint [8] 0 0
Week 16
Secondary outcome [9] 0 0
Change From Baseline in Psoriasis Symptom and Sign Diary (PSSD) Symptom Score at Week 16 in the Guselkumab Group Compared to the Placebo Group
Timepoint [9] 0 0
Baseline and Week 16
Secondary outcome [10] 0 0
Percentage of Participants Who Achieved a Psoriasis Symptom and Sign Diary (PSSD) Symptom Score of 0 in the Guselkumab Group Compared to the Adalimumab Group at Week 24
Timepoint [10] 0 0
Week 24
Secondary outcome [11] 0 0
Percentage of Participants Who Achieved PASI 90 Response at Week 252
Timepoint [11] 0 0
Week 252
Secondary outcome [12] 0 0
Percentage of Participants Who Achieved PASI 75 Response at Week 252
Timepoint [12] 0 0
Week 252
Secondary outcome [13] 0 0
Percentage of Participants Who Achieved an IGA Score of Cleared (0) or Minimal (1) at Week 252
Timepoint [13] 0 0
Week 252
Secondary outcome [14] 0 0
Percentage of Participants With a DLQI Score of 0 or 1 at Week 252
Timepoint [14] 0 0
Week 252
Secondary outcome [15] 0 0
Percentage of Participants Who Achieved a PSSD Symptom Score of 0 at Week 252
Timepoint [15] 0 0
Week 252
Secondary outcome [16] 0 0
Percentage of Participants Who Achieved a PSSD Sign Score of 0 at Week 252
Timepoint [16] 0 0
Week 252

Eligibility
Key inclusion criteria
- Have a diagnosis of plaque-type psoriasis (with or without psoriatic arthritis) at
least 6 months before the first administration of study agent

- Have a Psoriasis Area and Severity Index (PASI) greater than or equal to (>=) 12 at
Screening and at Baseline

- Have an Investigator's Global Assessment (IGA) score >=3 at Screening and at Baseline

- Have an involved body surface area (BSA) >=10 percent (%) at Screening and at Baseline

- Must be a candidate for either systemic therapy or phototherapy for psoriasis
Minimum age
18 Years
Maximum age
99 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Participants with nonplaque forms of psoriasis (for example, erythrodermic, guttate,
or pustular) or with current drug-induced psoriasis (for example, a new onset of
psoriasis or an exacerbation of psoriasis from beta blockers, calcium channel
blockers, or lithium)

- Participants who have ever received guselkumab or adalimumab

- History or current signs or symptoms of severe, progressive, or uncontrolled renal,
hepatic, cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic,
hematologic, rheumatologic, psychiatric, or metabolic disturbances

- Has any condition that, in the opinion of the investigator, would make participation
not be in the best interest (for example, compromise the well-being) of the
participant or that could prevent, limit, or confound the protocol-specified
assessments

- Is pregnant, nursing, or planning a pregnancy (both men and women) within 5 months
following the last administration of study drug

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
26/11/2014
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
17/06/2020
Sample size
Target
Accrual to date
Final
837
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
- Darlinghurst
Recruitment hospital [2] 0 0
- East Melbourne
Recruitment hospital [3] 0 0
- Hectorville
Recruitment hospital [4] 0 0
- Liverpool
Recruitment hospital [5] 0 0
- Melbourne
Recruitment hospital [6] 0 0
- Westmead
Recruitment hospital [7] 0 0
- Woden
Recruitment hospital [8] 0 0
- Woolloongabba
Recruitment postcode(s) [1] 0 0
- Darlinghurst
Recruitment postcode(s) [2] 0 0
- East Melbourne
Recruitment postcode(s) [3] 0 0
- Hectorville
Recruitment postcode(s) [4] 0 0
- Liverpool
Recruitment postcode(s) [5] 0 0
- Melbourne
Recruitment postcode(s) [6] 0 0
- Westmead
Recruitment postcode(s) [7] 0 0
- Woden
Recruitment postcode(s) [8] 0 0
- Woolloongabba
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Colorado
Country [3] 0 0
United States of America
State/province [3] 0 0
Connecticut
Country [4] 0 0
United States of America
State/province [4] 0 0
Florida
Country [5] 0 0
United States of America
State/province [5] 0 0
Georgia
Country [6] 0 0
United States of America
State/province [6] 0 0
Illinois
Country [7] 0 0
United States of America
State/province [7] 0 0
Indiana
Country [8] 0 0
United States of America
State/province [8] 0 0
Massachusetts
Country [9] 0 0
United States of America
State/province [9] 0 0
Michigan
Country [10] 0 0
United States of America
State/province [10] 0 0
Minnesota
Country [11] 0 0
United States of America
State/province [11] 0 0
Missouri
Country [12] 0 0
United States of America
State/province [12] 0 0
New Jersey
Country [13] 0 0
United States of America
State/province [13] 0 0
New Mexico
Country [14] 0 0
United States of America
State/province [14] 0 0
Oregon
Country [15] 0 0
United States of America
State/province [15] 0 0
Pennsylvania
Country [16] 0 0
United States of America
State/province [16] 0 0
Rhode Island
Country [17] 0 0
United States of America
State/province [17] 0 0
Texas
Country [18] 0 0
United States of America
State/province [18] 0 0
Virginia
Country [19] 0 0
Canada
State/province [19] 0 0
Alberta
Country [20] 0 0
Canada
State/province [20] 0 0
British Columbia
Country [21] 0 0
Canada
State/province [21] 0 0
Newfoundland and Labrador
Country [22] 0 0
Canada
State/province [22] 0 0
Nova Scotia
Country [23] 0 0
Canada
State/province [23] 0 0
Ontario
Country [24] 0 0
Canada
State/province [24] 0 0
Quebec
Country [25] 0 0
Germany
State/province [25] 0 0
Berlin
Country [26] 0 0
Germany
State/province [26] 0 0
Bonn
Country [27] 0 0
Germany
State/province [27] 0 0
Dresden
Country [28] 0 0
Germany
State/province [28] 0 0
Essen
Country [29] 0 0
Germany
State/province [29] 0 0
Frankfurt/ Main
Country [30] 0 0
Germany
State/province [30] 0 0
Gera
Country [31] 0 0
Germany
State/province [31] 0 0
Hamburg
Country [32] 0 0
Germany
State/province [32] 0 0
Kiel
Country [33] 0 0
Germany
State/province [33] 0 0
Lubeck
Country [34] 0 0
Germany
State/province [34] 0 0
Mahlow
Country [35] 0 0
Germany
State/province [35] 0 0
Munster
Country [36] 0 0
Germany
State/province [36] 0 0
Tübingen
Country [37] 0 0
Hungary
State/province [37] 0 0
Budapest
Country [38] 0 0
Hungary
State/province [38] 0 0
Debrecen
Country [39] 0 0
Hungary
State/province [39] 0 0
Kaposvar
Country [40] 0 0
Hungary
State/province [40] 0 0
Kecskemet
Country [41] 0 0
Hungary
State/province [41] 0 0
Pecs
Country [42] 0 0
Hungary
State/province [42] 0 0
Szeged
Country [43] 0 0
Korea, Republic of
State/province [43] 0 0
Bundang
Country [44] 0 0
Korea, Republic of
State/province [44] 0 0
Busan
Country [45] 0 0
Korea, Republic of
State/province [45] 0 0
Daejeon
Country [46] 0 0
Korea, Republic of
State/province [46] 0 0
Seoul
Country [47] 0 0
Korea, Republic of
State/province [47] 0 0
Suwon
Country [48] 0 0
Poland
State/province [48] 0 0
Bialystok
Country [49] 0 0
Poland
State/province [49] 0 0
Bydgoszcz
Country [50] 0 0
Poland
State/province [50] 0 0
Lodz
Country [51] 0 0
Poland
State/province [51] 0 0
Olsztyn
Country [52] 0 0
Poland
State/province [52] 0 0
Warszawa
Country [53] 0 0
Poland
State/province [53] 0 0
Wroclaw
Country [54] 0 0
Russian Federation
State/province [54] 0 0
Ekaterinburg
Country [55] 0 0
Russian Federation
State/province [55] 0 0
Kirov
Country [56] 0 0
Russian Federation
State/province [56] 0 0
Krasnodar
Country [57] 0 0
Russian Federation
State/province [57] 0 0
Lipetsk
Country [58] 0 0
Russian Federation
State/province [58] 0 0
Moscow
Country [59] 0 0
Russian Federation
State/province [59] 0 0
Rostov-on-Don
Country [60] 0 0
Russian Federation
State/province [60] 0 0
Ryazan
Country [61] 0 0
Russian Federation
State/province [61] 0 0
St. Petersburg
Country [62] 0 0
Russian Federation
State/province [62] 0 0
Stavropol
Country [63] 0 0
Russian Federation
State/province [63] 0 0
Ulyanovsk
Country [64] 0 0
Spain
State/province [64] 0 0
Baracaldo
Country [65] 0 0
Spain
State/province [65] 0 0
Barcelona
Country [66] 0 0
Spain
State/province [66] 0 0
Cordoba
Country [67] 0 0
Spain
State/province [67] 0 0
Madrid
Country [68] 0 0
Spain
State/province [68] 0 0
Manises
Country [69] 0 0
Spain
State/province [69] 0 0
Palma de Mallorca
Country [70] 0 0
Spain
State/province [70] 0 0
Salamanca
Country [71] 0 0
Spain
State/province [71] 0 0
San Sebastian de los Reyes
Country [72] 0 0
Spain
State/province [72] 0 0
Valencia
Country [73] 0 0
Taiwan
State/province [73] 0 0
Kaohsiung
Country [74] 0 0
Taiwan
State/province [74] 0 0
Taichung City
Country [75] 0 0
Taiwan
State/province [75] 0 0
Tainan
Country [76] 0 0
Taiwan
State/province [76] 0 0
Taipei City
Country [77] 0 0
Taiwan
State/province [77] 0 0
Taipei
Country [78] 0 0
Taiwan
State/province [78] 0 0
Taoyuan

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Janssen Research & Development, LLC
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to evaluate the efficacy, safety, and tolerability of guselkumab
(CNTO 1959) in the treatment of participants with moderate to severe plaque-type psoriasis.
Trial website
https://clinicaltrials.gov/ct2/show/NCT02207231
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Janssen Research & Development, LLC Clinical Trial
Address 0 0
Janssen Research & Development, LLC
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT02207231